恩格列净在射血分数保留心衰中不受年龄影响改善结局
EMPEROR-Preserved 试验按年龄分组分析 5988 例射血分数保留心衰患者,发现恩格列净降低主要结局、首次及反复心衰住院的效应在各年龄组一致,高龄不降低疗效且不增加临床相关不良事件。
要点
- 恩格列净降低主要结局和心衰住院的疗效在各年龄组一致
- 高龄(≥75岁或>80岁)不减弱恩格列净的疗效
- 各年龄组恩格列净与安慰剂的不良事件无临床相关差异
核心结论
- 恩格列净在广泛年龄范围内降低主要结局、首次和反复心衰住院并改善症状。
- 高龄与疗效降低或临床不可耐受无关。
研究设计与样本
- EMPEROR-Preserved 试验的事后年龄亚组分析,共纳入 5988 例射血分数保留心衰患者。
- 按基线年龄分为<65岁(n=1199)、65-74岁(n=2214)、75-79岁(n=1276)、≥80岁(n=1299)四组。
主要发现
- 仅安慰剂组中,主要结局(P trend=0.02)和心血管死亡(P trend=0.003)发生率随年龄增长而升高。
- 恩格列净降低主要结局(P trend=0.33)、首次心衰住院(P trend=0.22)、首次和反复心衰住院(P trend=0.11)在各年龄组效应相似。
- ≥75岁(P interaction=0.22)或>80岁(P interaction=0.51)亚组疗效无显著交互作用。
- 恩格列净改善第52周KCCQ-CSS并减缓eGFR下降,无年龄交互作用(P=0.48和P=0.32)。
- 各年龄组恩格列净与安慰剂的不良事件无临床相关差异。
临床怎么用
- 对射血分数保留心衰患者,恩格列净的疗效和安全性不受年龄限制,高龄患者同样可获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Empagliflozin reduces cardiovascular death (CVD) or heart failure (HF) hospitalization (HFH) in patients with HF and preserved ejection fraction. Treatment effects and safety in relation to age have not been studied. OBJECTIVES: The purpose of this study was to evaluate the interplay of age and empagliflozin effects in EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction). METHODS: We grouped patients (n = 5,988) according to their baseline age (<65 years [n = 1,199], 65-74 years [n = 2,214], 75-79 years [n = 1,276], ≥80 years [n = 1,299]). We explored the influence of age on empagliflozin effects on CVD or HFH (primary outcome), total HFH, rate of decline in estimated glomerular filtration rate, health-related quality of life with the Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score, and frequency of adverse events. RESULTS: Considering only patients on placebo, the incidence of primary outcomes (P trend = 0.02) and CVD (P trend = 0.003) increased with age. Empagliflozin reduced primary outcomes (P trend = 0.33), first HFH (P trend = 0.22), and first and recurrent HFH (P trend = 0.11) across all age groups with an effect being similar at ≥75 years (P interaction = 0.22) or >80 years (P interaction = 0.51). Empagliflozin improved Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score at week 52 and attenuated the decline of estimated glomerular filtration rate without age interaction (P = 0.48 and P = 0.32, respectively). There were no clinically relevant differences in adverse events between empagliflozin and placebo across the age groups. CONCLUSIONS: Empagliflozin reduced primary outcomes and first and recurrent HFH and improved symptoms across a broad age spectrum. High age was not associated with reduced efficacy or meaningful intolerability. (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction [EMPEROR-Preserved]; NCT0305951).
引用
- Böhm M, Butler J, Filippatos G, et al. Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age. J Am Coll Cardiol. 2022. PMID: 35772911. doi:10.1016/j.jacc.2022.04.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。